Phase 3 study planned to evaluate therapy platform for mild cognitive impairment

Cognito Therapeutics and Providence Health Plan will collaborate on a phase 3 study of a noninvasive therapy for patients with mild cognitive impairment, according to a release.

“Novel technologies, such as Cognito’s disease-modifying treatment are critical to improve patient outcomes in MCI,” Nancy Isenberg, MD, MPH, medical director of the Center for Healthy Aging at the Swedish Neuroscience Institute, said in the release. “There are currently no drugs that have been approved for treating MCI, and patients need new safe, effective and affordable options.”

The upcoming trial, which is expected to begin in the second quarter of 2022, will evaluate the safety, efficacy and cost-effectiveness of the Cognito therapy in MCI patients treated by neurology specialists within the Providence Health Plan network. It will run concurrently with a Cognito phase 3 study of patients with mild to moderate Alzheimer’s disease.

The collaboration is part of a larger phase 3 program to assess the Cognito disease-modifying, optogenetics-based therapeutic platform in patients diagnosed with MCI and mild-to-moderate AD.

“Our proprietary therapeutic platform holds the potential to create an entirely new approach to clinically meaningful improvements in patients across a broad range of conditions of neurodegeneration and neuropsychiatry,” Brent Vaughan, CEO of Cognito Therapeutics, said in the release.